Armistice Capital’s Avanos Medical AVNS Stock Holding History

Armistice Capital’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,000,000	Closed	-$28M	–	342
2026 Q1	$28M	Sell	2,000,000 -1,200,000	-38%	-$16.2M	0.5%	34
2025 Q4	$35.9M	Buy	3,200,000 +700,000	+28%	+$8.01M	0.43%	39
2025 Q3	$28.9M	Buy	2,500,000 +464,000	+23%	+$5.43M	0.43%	35
2025 Q2	$24.9M	Buy	2,036,000 +36,000	+2%	+$453K	0.43%	34
2025 Q1	$28.7M	Buy	+2,000,000	New	+$31.2M	0.43%	48
2021 Q1	–	Sell	-156,000	Closed	-$7.16M	–	112
2020 Q4	$7.16M	Sell	156,000 -41,000	-21%	-$1.71M	0.24%	74
2020 Q3	$6.54M	Buy	+197,000	New	+$6.3M	0.24%	73

Other funds holding AVNS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.5B AUM 83.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Armistice Capital's AVNS Position: Q2 2026 in Review

Armistice Capital sold out of Avanos Medical (AVNS) in Q2 2026, closing a stake of 2,000,000 shares — an estimated $28M sold.

Armistice Capital first reported a position in AVNS in Q3 2020 and held it in 7 quarters. The position peaked at $35.9M in Q4 2025. 286 funds tracked by Wall St. Rank hold AVNS as of Q2 2026.

Armistice Capital reported no remaining Avanos Medical position as of Q2 2026 after selling out during the quarter.
Armistice Capital sold 2,000,000 Avanos Medical shares in Q2 2026, an estimated $28M.
Armistice Capital first reported a position in Avanos Medical in Q3 2020 and held it in 7 quarters.
Armistice Capital's Avanos Medical position peaked at $35.9M in Q4 2025.
286 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.